Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent plasma transfusion for respiratory failure in adults with COVID-19
IRCT20200406046968N2Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- May 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of COVID-19 convalescent plasma in coronavirus disease 2019 (COVID-19), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Convalescent plasma transfusion, P/F ratio and 8 more. Started May 2020; status: completed.
02
Drugs
COVID-19 convalescent plasma
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200406046968N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200406046968N2.